首页 中大制药(usCNAT)-基本信息

中大制药(usCNAT)-基本信息

日报更新时间:

周报更新时间:01-23 11:54

行情信息

今开价:

最高价:

成交量:

昨收价:

最低价:

最新价:

行情图标
概要信息

中文名称:中大制药


英文名称:Conatus Pharmaceuticals


简介:Conatus Pharmaceuticals Inc.于2005年7月13日在特拉华州注册成立


电话:1-858-3762600


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Conatus Pharmaceuticals是一家生物技术公司,专注于治疗肝病的新药的开发和商业化。Conatus Pharmaceuticals的主要化合物产品Emricasan是一种一流的口服活性泛半胱天冬酶蛋白酶抑制剂,旨在降低人类半胱天冬酶的活性,这是一种介导炎症和细胞凋亡的酶。公司相信通过降低这些酶的活性,emricasan有可能阻断肝脏疾病的进展,并可能在肝脏疾病的多个领域提供治疗选择。目前处于原位肝移植后丙型肝炎病毒感染的 IIb 期临床试验中。Conatus Pharmaceuticals观察到令人信服的临床前和临床试验结果表明,无论原始疾病的原因如何,emricasan可能在减缓肝脏疾病进展方面具有临床效用。迄今为止,emricasan已在16项临床试验中对650多名受试者进行了研究,这些临床试验涉及广泛的肝病病因和进展阶段。在多项临床试验中,emricasan已显示出与肝病严重程度和进展有关的炎症和细胞凋亡关键生物标志物水平的统计学显着,一致,快速和持续的降低。重要的是,已知这些关键生物标志物在目前正在追求的多种肝脏适应症中升高并具有预后价值。2016年12月,Conatus宣布与诺华公司就emricasan的全球发展和商业化达成独家选择、合作和许可协议。2017年5月,Conatus宣布诺华公司在开始进行 IIb 期ENCORE-LF临床试验后已行使其许可选项。

交易日期 交易人 职位 类型 交易份额 价格
2018-11-13 Ripley (Daniel L.) Officer Buy 1861 3.15
2018-11-13 Smith Edward F Iii Officer Buy 1724 3.15
2018-05-13 Ripley (Daniel L.) Officer Buy 1290 3.31
2018-05-13 Smith Edward F Iii Officer Buy 4690 3.31
2018-05-03 Mento (Steven J) Chief Executive Officer Buy 60000 0.99
2018-02-26 Spada (Alfred P) Officer Buy 12121 1.24
2017-11-13 Ripley (Daniel L.) Officer Buy 818 3.48
2017-11-13 Smith Edward F Iii Officer Buy 4461 3.48

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
D. E. Shaw & Co LP 87667 0.26% 25504 41.03% 2019-03-31
Geode Capital Management, LLC 239083 0.72% -177609 -42.62% 2019-03-31
Acadian Asset Management LLC 245078 0.74% 245078 -- 2019-03-31
Parallax Volatility Advisers, LLC 329751 0.99% 226571 219.59% 2019-03-31
BlackRock Fund Advisors 872939 2.63% -65395 -6.97% 2019-07-31
Vanguard Investments Australia Ltd 1274567 3.84% -- -- 2019-07-31
BlackRock Inc 1562521 4.71% -49531 -3.07% 2019-03-31
Vanguard Group Inc 1638895 4.94% 1050759 178.66% 2019-03-31
Mpm Asset Management, LLC 2464807 7.43% -- -- 2019-03-31
Fidelity Management & Research Company 226082 0.68% -84437 -27.19% 2019-07-31
BlackRock Advisors LLC 225141 0.68% -- -- 2019-07-31
Hikari Power Ltd 200488 0.60% 33200 19.85% 2019-03-31
Bank of America Corporation 92104 0.28% -179 -0.19% 2019-03-31
QS Investors LLC 96807 0.29% -- -- 2019-03-31
Vassalluzzo Scott J 124643 0.38% 20200 19.34% 2019-03-31
Susquehanna International Group, LLP 130379 0.39% 8504 6.98% 2019-03-31
Susquehanna Financial Group, LLLP 130379 0.39% 8504 6.98% 2019-03-31
Vanguard 158105 0.48% -- -- 2019-07-31
United Capital Financial Advisers Inc 175476 0.53% -63 -0.04% 2019-03-31
Bridgeway Capital Management, Inc 183300 0.55% 80000 77.44% 2019-03-31
Mellon Investments Corporation 137500 0.41% -- -- 2018-12-31
Bank of New York Mellon Corp 160069 0.48% -1380 -0.85% 2018-12-31
BOOTHBAY FUND MANAGEMENT, LLC 189255 0.57% 189255 -- 2018-12-31
Sofinnova Ventures 638197 1.92% 99282 18.42% 2018-12-31
Group One Trading, LP 217600 0.66% -22328 -9.31% 2018-12-31
Two Sigma Investments LLC 250085 0.75% 221044 761.14% 2018-12-31
BlackRock Institutional Trust Company NA 121281 0.37% 121281 -- 2019-03-31
Artal Group S A 500000 1.51% 500000 -- 2018-09-30
AXA SA 443624 1.34% -- -- 2018-09-30
Courage Capital Management, LLC 150050 0.45% -92950 -38.25% 2018-09-30
BNY Mellon Asset Management North America Corporation 137500 0.41% -- -- 2018-09-30
AXA Investment Managers UK Ltd 443624 1.34% -- -- 2018-12-31
AQR Capital Management LLC 178093 0.59% -18071 -9.21% 2018-11-30
Charles Schwab Investment Management Inc 180556 0.60% -- -- 2018-11-30
Crestline Management LP 252723 0.84% 252723 -- 2018-06-30
Goldman Sachs Group Inc 418995 1.38% 331475 378.74% 2018-06-30
AllianceBernstein L.P. 443624 1.47% -- -- 2018-09-30
Millennium Management LLC 369124 1.22% 11445 3.20% 2018-06-30
Goldman, Sachs & Co. 407896 1.35% 320376 366.06% 2018-06-30
Panagora Asset Management Inc 133411 0.44% -19564 -12.79% 2018-03-31
Alambic Investment Management, L.P. 264665 0.88% 178461 207.02% 2018-06-30
Merrill Lynch & Co Inc 139880 0.46% 62552 80.89% 2018-06-30
Mellon Capital Management Corporation 137500 0.46% -13750 -9.09% 2018-06-30
Sunrise Partners LLC 127799 0.42% 127799 -- 2018-06-30
Element Capital Management LLC 125749 0.42% 125749 -- 2018-06-30
BlueCrest Capital Management Ltd. 97184 0.32% 97184 -- 2018-06-30
Morgan Stanley & Co Inc 78339 0.26% 21254 37.23% 2018-06-30
Oxford Asset Management, LLC 56669 0.19% -51698 -47.71% 2018-03-31
Springbok Capital Management, LLC 55008 0.18% 55008 -- 2018-03-31
Arrowstreet Capital Limited Partnership 124064 0.41% -17636 -12.45% 2018-03-31
Morgan Stanley Smith Barney LLC 82976 0.28% 31902 62.46% 2018-03-31
TIAA-CREF Investment Management LLC 141812 0.47% -74954 -34.58% 2018-03-31
Northern Trust Investments N A 294617 0.98% 9216 3.23% 2018-03-31
MPM BioVentures IV QP LP 2464807 9.42% 2464807 -- 2017-05-11
AllianceBernstein LP 448779 1.49% -4138 -0.91% 2018-03-31
State Street Corp 411838 1.37% 9424 2.34% 2018-03-31
American Century Inv Mgt Inc 109571 0.36% 109571 -- 2018-03-31
Invesco Advisers, Inc 152890 0.51% 152890 -- 2017-12-31
Sterling Capital Management LLC 129011 0.43% 129011 -- 2017-09-30
Numeric Investors LLC 260451 0.87% -20847 -7.41% 2017-09-30
Bogle Investment Management L P 174512 0.58% -301090 -63.31% 2017-09-30
MPM BioVentures IV LLC 612149 2.34% 16110 2.70% 2016-12-31
MPM BioVentures V LLC 612151 2.34% 16110 2.70% 2016-12-31
Polar Capital LLP 156531 0.62% -- -- 2016-09-30
KCG AMERICAS LLC 67748 0.27% 67748 -- 2016-09-30
Renaissance Technologies Corp 62600 0.25% 62600 -- 2016-09-30
Credit Suisse First Boston (CSFB) 39018 0.15% 39018 -- 2016-09-30
Reilly Financial Advisors, LLC 32011 0.13% -- -- 2016-09-30
Wedbush Morgan Securities Inc 28500 0.11% 10500 58.33% 2016-09-30
FNY Managed Accounts LLC 27000 0.11% 27000 -- 2016-09-30
Louis Lacasse 809887 4.00% 5110387 -- 1999-11-30
Entities affiliated with HealthCor Management, L.P. 1001458 4.00% 6319200 0.10% 1999-11-30
James Scopa 1192080 4.00% 7522025 0.10% 1999-11-30
Shahzad Malik, M.D. 2166836 4.00% 13672735 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
BlackRock Extended Equity Market 56951 0.17% -78 -0.14% 2019-06-30
Vanguard Total Stock Market Index Fund 1274567 3.84% -- -- 2019-06-30
Vanguard Extended Market Index Fund 362868 1.09% -- -- 2019-06-30
Bridgeway Ultra Small Company Market Fd 160000 0.48% 80000 100.00% 2019-03-31
Vanguard VIF Small Co Gr Portfolio 152005 0.46% -- -- 2019-03-31
BlackRock Advantage Small Cap Core Fund 115372 0.35% -- -- 2019-06-30
BlackRock Advantage Small Cap Growth Fd 109769 0.33% -- -- 2019-06-30
BlackRock US SmCp Eq BigData Strat MF 72288 0.22% 72288 -- 2019-03-20
Vanguard Instl Total Stock Market Idx Fd 33608 0.10% -- -- 2019-06-30
NT Extended Equity Market Idx Fund - NL 27140 0.08% -- -- 2019-06-30
State Street U.S. Extended Market Index 15800 0.05% -- -- 2019-06-30
NT Ext Equity Mkt Fd - DC - NL 19419 0.06% 1413 7.85% 2019-06-30
VALIC Company I Small Cap Fund 19500 0.06% -- -- 2019-05-31
MIP Active Stock Master Portfolio 21164 0.06% -- -- 2019-06-30
NT Ext Equity Market Index Fund - L 24347 0.07% -- -- 2019-06-30
Vanguard Balanced Index Fund 26615 0.08% -- -- 2019-06-30
Fidelity 26802 0.08% -- -- 2019-06-30
Wells Fargo Factor Enhanced Sm Cp IdxCIT 13369 0.04% -19763 -59.65% 2019-06-30
BNYM Mellon NSL Mkt Completion Fd Instl 20798 0.06% 20083 2808.81% 2019-03-31
Wells Fargo Factor Enhanced Small Cap 21054 0.06% -- -- 2019-05-31
QS US Small Capitalization Equity CIF 74481 0.22% -- -- 2019-03-31
QS US Small Capitalization Equity Fund 21766 0.07% -- -- 2019-03-31
iShares Micro-Cap ETF 72799 0.22% -- -- 2019-06-27
BNYM Mellon SL Mkt Completion Fd 20798 0.06% 20083 2808.81% 2019-03-31
BSF Americas Diversified Eq Abs Ret Fd 121281 0.37% 121281 -- 2018-12-31
Diamond Flexible 15811 0.05% -34889 -68.81% 2019-01-31
SPDR 17236 0.05% -286 -1.63% 2019-03-29
MEDICAL BioHealth 58181 0.18% -- -- 2018-11-30
iShares Russell 2000 Growth ETF 259489 0.78% 448 0.17% 2018-06-21
iShares Russell 3000 ETF 16280 0.05% -- -- 2018-06-21
FCP MEDICAL BioHealth-Trends 58181 0.18% -- -- 2018-10-31
APO Medical Opportunities 30273 0.09% -17000 -35.96% 2018-11-30
OMI IM GBP AXA Framlington Biotech 443624 1.34% -- -- 2018-11-30
Schwab Small-Cap Equity Fund 136356 0.45% -- -- 2018-03-31
AQR Small Cap Multi-Style Fund 129965 0.43% -16052 -10.99% 2018-03-31
Hartford Small Cap Value Fund 46979 0.16% -- -- 2018-03-31
AXA 2000 Managed Volatility Portfolio 38752 0.13% -- -- 2018-05-31
AQR Small Cap Momentum Style Fund 37639 0.12% -- -- 2018-03-31
American Century Small Company Fund 59586 0.20% 59586 -- 2018-03-31
FCP MEDICAL BioHealth 58181 0.19% -- -- 2018-06-30
Sterling Capital Behav Sm Cp Val Eq Fd 128033 0.42% -- -- 2017-11-30
BNY Mellon EB DL Mkt Completion 20837 0.07% -- -- 2018-06-30
Vanguard Balanced Index Inv 21492 0.07% -- -- 2018-07-31
VALIC Company I Small Cap 19500 0.06% -- -- 2018-07-31
QS Batterymarch US Sm Cap Eq I 21766 0.06% -- -- 2018-06-30
MIP Active Stock Master 28034 0.09% -- -- 2018-07-31
Fidelity Spartan 36543 0.12% -- -- 2018-07-31
Vanguard Instl Ttl Stk Mkt Idx InstlPls 39393 0.13% -- -- 2018-07-31
Vanguard Total Stock Mkt Idx 765014 2.54% -- -- 2018-07-31
Vanguard Extended Market Idx Inv 367168 1.22% -- -- 2018-07-31
Vanguard VIF Small Co Gr 152005 0.50% -- -- 2018-06-30
State Street Russell Small/Mid Cap Idx Fd Cl I 110100 0.37% 110100 -- 2017-06-30
BlackRock Small Cap Growth Eq Instl 151991 0.50% -1411 -0.92% 2018-07-31
Bridgeway Ultra-Small Company Market 113000 0.37% -- -- 2018-06-30
BlackRock Disciplined Small Cp Cor Inv A 88198 0.29% -- -- 2018-07-31
iShares Micro-Cap 71400 0.19% -- -- 2018-09-12
BlackRock Extended Equity Market K 56564 0.19% 1538 2.80% 2018-06-30
Fidelity VIP Discp Small Cap Inv 30448 0.10% -6856 -18.38% 2018-03-31
Invesco All Cap Market Neutral A 21900 0.07% -26700 -54.94% 2018-03-31
TIAA-CREF Small-Cap Blend Idx Inst 30219 0.10% -- -- 2018-05-31
CREF Stock R1 51360 0.17% -71800 -58.30% 2018-04-30
LVIP SSgA Small Cap Index Std 19000 0.06% -- -- 2018-03-31
AXA 2000 Managed Volatility K 38752 0.13% -- -- 2018-05-31
AQR Small Cap Momentum Style I 37639 0.13% -- -- 2018-03-31
AQR Small Cap Multi-Style N 129965 0.43% -16052 -10.99% 2018-03-31
Schwab Small-Cap Equity 136356 0.45% -- -- 2018-03-31
American Century Small Company Inv 59586 0.20% 59586 -- 2018-03-31
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 65123 0.22% 477 0.74% 2018-05-31
American Century NT Small Company Instl 35768 0.12% 35768 -- 2018-03-31
Schwab Small Cap Index 44200 0.15% -- -- 2018-05-31
The Vanguard Russell 2000 Growth Index 43564 0.14% 2695 6.59% 2018-05-31
BlackRock Russell 2500 32751 0.11% -1216 -3.58% 2018-03-31
BlackRock Russell 2000 38526 0.13% 364 0.95% 2018-03-31
iShares Russell 2000 Growth 259489 1.00% 448 0.17% 2018-06-21
Hartford Small Cap Core A 46979 0.16% -- -- 2018-03-31
Sterling Capital Behav Sm Cp Val Eq Intl 128033 0.43% -- -- 2017-11-30
Wilshire Micro-Cap ETF 6452 0.03% -- -- 2017-02-08
The Vanguard Total Stock Market Index 6100 0.02% -- -- 2016-12-31
iShares Core S&P Total US Stock Mkt 4382 0.02% -- -- 2017-02-07
AXA/Lord Abbett Micro Cap K 2650 0.01% -- -- 2016-11-30
BNY Mellon Market Completion Fund UC1 626 -- 12 1.95% 2016-12-31
BlackRock LifePath 35 -- 12 52.17% 2016-03-31
Weiss Alternative Balanced Risk I 6 -- 6 -- 2016-12-31
Putnam Global Health Care Fund 171528 0.90% -- -- 2015-09-30
Polar Capital Glb Healthcare Gr & Inc 156531 0.80% -- -- 2015-09-30
Bridgeway Ultra Small Company Market 65000 0.30% -- -- 2015-09-30
Fidelity Spartan® Extended Mkt Indx Fd 52030 0.30% -- -- 2015-09-30
Prudential Jennison Health Sciences 522993 2.60% -- -- 2015-09-30
Putnam VT Global Health Care 18999 0.10% -- -- 2015-09-30
BlackRock Health Sciences 8200 -- -- -- 2015-06-30
Mellon Capital EB DL Mkt Completion Fund 7186 -- -- -- 2015-09-30
BlackRock Extended Equity Market Fund 6988 -- 6988 -- 2015-09-30
Fidelity Spartan® Total Market Idx Fund 19091 0.10% -- -- 2015-09-30

David F. Hale Mr. David F. Hale is a Chairman at Adigica Health, Inc., a Chairman at Recros Medica, Inc., an Executive Chairman at MDRejuvena, Inc., a Chairman at Agility Clinical, Inc., a Non-Executive Chairman at Biocept, Inc., a Chairman at Advantar Laboratories, Inc., a Chairman at Conatus Pharmaceuticals, Inc., a Chairman at Hale BioPharma Ventures LLC, an Advisor at Windamere Venture Partners LLC, a Chairman at Clarify Medical, Inc., a Chairman at Intrepid Therapeutics, Inc., a Chairman at Oncternal Therapeutics, Inc., a Chairman at Rady Children's Institute for Genomic Medicine, a Chairman at Rich Diagnostics, Inc., a Chairman at Ridge Diagnostics, Inc., an Executive Chairman at Neurana Pharmaceuticals, Inc. and a General Partner at Hale Trading Co. LP. He is on the Board of Directors at Neurelis, Inc., BIOCOM, Dermata Therapeutics LLC, Idun Pharmaceuticals, Inc., San Diego Regional Economic Development Corp., Rady Children's Hospital & Health Center of San Diego and The Salk Institute for Biological Studies.
David T. Hagerty David T. Hagerty is Executive Vice President-Clinical Development at Conatus Pharmaceuticals, Inc. In his past career Dr. Hagerty held the position of Chief Medical Officer & Senior Vice President for Ardea Biosciences, Inc., Executive Director-Immunology at Bristol-Myers Squibb Pharmaceutical Research Institute and Vice President-Immunology & Rheumatology at Biogen Idec, Inc. (North Carolina). He received an undergraduate degree from the University of Notre Dame and a doctorate from Saint Louis University School of Medicine.
Daniel L. Kisner Daniel L. Kisner is a businessperson who has been at the head of 7 different companies and currently holds the position of Chairman at Idun Pharmaceuticals, Inc. He is also on the board of 6 other companies. He previously was Chairman for Arbutus Biopharma Corp., Chairman for Caliper Technologies Corp., Chairman for Avera Pharmaceuticals, Inc., Chairman for Sequoia Pharmaceuticals, Inc., President & Chief Operating Officer for Ionis Pharmaceuticals, Inc., Partner at Aberdare Ventures, Vice President-Pharmaceutical Development at Abbott Laboratories, Chairman for Caliper Life Sciences, Inc. and Vice President-Clinical Research & Development at Smithkline Beckman Corp. Daniel L. Kisner received a doctorate from Georgetown University and an undergraduate degree from Rutgers State University of New Jersey.
William R. LaRue Mr. William R. LaRue is an Independent Director at Conatus Pharmaceuticals, Inc. and an Independent Director at TRACON Pharmaceuticals, Inc. He is on the Board of Directors at Oncternal Therapeutics, Inc., Conatus Pharmaceuticals, Inc., Applied Proteomics, Inc., TRACON Pharmaceuticals, Inc. and ALASTIN Skincare, Inc. Mr. LaRue was previously employed as a CFO, Treasurer, Director & Senior VP by Cadence Pharmaceuticals, Inc., a Chief Financial Officer & Senior Vice President by Amgen Rockville, Inc., a Chief Financial Officer & Senior VP by CancerVax Corp., a Chief Financial Officer & Executive Vice President by eHelp Corp., a Treasurer & Vice President by Safeskin Corp., and a Treasurer by GDE Systems, Inc. He also served on the board at Oncternal Oncology, Inc. and Neurelis, Inc. He received his undergraduate degree from the University of Southern California and an MBA from the University of Southern California.
Harold E. van Wart Harold E. van Wart is on the board of Idun Pharmaceuticals, Inc. and Conatus Pharmaceuticals, Inc. In his past career he was Chairman for California Biomedical Innovation Alliance and Chairman at The Bay Area Bioscience Association (a subsidiary of California Biomedical Innovation Alliance), President, Chief Executive Officer & Director at CymaBay Therapeutics, Inc., Vice President & Head-Therapy-Roche Bioscience at Syntex Corp. and Faculty Member at Florida State University. Harold E. van Wart received a doctorate from Cornell University and an undergraduate degree from State University of New York at Binghamton.
Steven J. Mento Steven J. Mento founded Conatus Pharmaceuticals, Inc. Presently, he is President, Chief Executive Officer & Director at this company. Dr. Mento is also on the board of BIOCOM, BIO Emerging Co. and Donald P. Shiley Bioscience Center and Director & Member-Health Section at Biotechnology Innovation Organization. Dr. Mento previously held the position of Vice President-Research & Development of Viagene, Inc., Director-Viral Vaccine Research & Development at Lederle Praxis Biological, Inc., President, Chief Executive Officer & Director at Idun Pharmaceuticals, Inc., Vice President-Research & Development at Chiron Viagene, Inc., Vice President-Research & Development at Chiron Corp. and Assistant Research Professor at Icah School of Medicine at Mount Sinai. He received a doctorate, a graduate degree and an undergraduate degree from Rutgers State University of New Jersey.
Alfred P. Spada Founder of Conatus Pharmaceuticals, Inc., Alfred P. Spada presently is CSO, Executive VP-Research & Development at this company. In the past Dr. Spada was Department Director at Aventis Pharmaceuticals, Inc., Department Director at Rhone Poulenc AG, Inc., Principal at Rorer Pharmaceuticals, Inc. and VP-Pharmaceutical & Preclinical Development at Idun Pharmaceuticals, Inc. Alfred P. Spada received an undergraduate degree from Worcester Polytechnic Institute and a doctorate from Massachusetts Institute of Technology.
Alan R. Engbring Presently, Alan R. Engbring is Executive Director-IR & Communications at Conatus Pharmaceuticals, Inc. In the past Mr. Engbring occupied the position of Executive Director-Investor Relations at Vical, Inc.
Alfred P. Spada Founder of Conatus Pharmaceuticals, Inc., Alfred P. Spada presently is CSO, Executive VP-Research & Development at this company. In the past Dr. Spada was Department Director at Aventis Pharmaceuticals, Inc., Department Director at Rhone Poulenc AG, Inc., Principal at Rorer Pharmaceuticals, Inc. and VP-Pharmaceutical & Preclinical Development at Idun Pharmaceuticals, Inc. Alfred P. Spada received an undergraduate degree from Worcester Polytechnic Institute and a doctorate from Massachusetts Institute of Technology.
Alan R. Engbring Alan R. Engbring occupies the position of Executive Director-IR & Communications at Conatus Pharmaceuticals, Inc. In his past career Mr. Engbring held the position of Executive Director-Investor Relations at Vical, Inc.
Edward F. Smith Edward F. Smith is Senior VP-Regulatory Affairs & Quality Assurance at Conatus Pharmaceuticals, Inc. In his past career Dr. Smith occupied the position of Vice President-Regulatory Affairs & Drug Safety at Zogenix, Inc., Director-Regulatory Affairs at Nektar Therapeutics, VP-Regulatory Affairs, Research & Development at Radiance Medical Systems, Inc., Principal at Mallinckrodt, Inc.(Old), Director-Corporate Regulatory Affairs at Valeant Pharmaceuticals International Corp., Principal at Smithkline Beecham Pharmaceuticals (India) Ltd., Senior Director-Regulatory Affairs at Stiefel Research Institute, Inc. and Senior Director-Regulatory Affairs at Connetics Corp. Edward F. Smith received a doctorate from Thomas Jefferson University, an undergraduate degree from Montana State University and an MBA from the University of Washington.
Preston S. Klassen Presently, Preston S. Klassen holds the position of Chief Medical Officer, EVP-Research & Development at Arena Pharmaceuticals, Inc. and President at Sanifit, Inc. Dr. Klassen is also on the board of Conatus Pharmaceuticals, Inc. and Corvidia Therapeutics, Inc. In his past career he was President & Chief Medical Officer at Sanifit Therapeutics SA, Executive Director-Medical at Amgen, Inc. and Executive Vice President-Global Development at Orexigen Therapeutics, Inc. Dr. Klassen received a doctorate from the University of Nebraska Medical Center and a graduate degree from Duke University.
Daniel L. Ripley Daniel L. Ripley is Senior VP-Business Development & Programme at Conatus Pharmaceuticals, Inc. In his past career Mr. Ripley occupied the position of Director-Business Development of Ionis Pharmaceuticals, Inc., Senior Director-Business Development at Kalypsys, Inc., Vice President-Business Development at BioBlocks, Inc., Director-Business Development for The Immune Response Corporation, Inc., Associate Director-Business Development at Orchestra Therapeutics, Inc. and Senior Director-Business Development at Apricus Biosciences, Inc. Mr. Ripley received an MBA and an undergraduate degree from San Diego State University.
Michelle L. Vandertie Presently, Michelle L. Vandertie is Principal Accounting Officer & VP-Finance at Conatus Pharmaceuticals, Inc. Ms. Vandertie previously occupied the position of Corporate Controller at California Structures, Controller at Vical, Inc., Chief Financial Officer for Ajinomoto Althea, Inc. and Auditor at Ernst & Young LLP. Michelle L. Vandertie received an undergraduate degree from the University of Northern Colorado.
Keith W. Marshall Founder of Montgomery, Marshall Healthcare Partners LLC, Keith W. Marshall presently is Executive VP, Chief Operating & Financial Officer at Conatus Pharmaceuticals, Inc. Dr. Marshall previously held the position of Chief Financial Officer & Managing Director at Montgomery, Marshall Healthcare Partners LLC, CFO & Head-Corporate Development at Torque Therapeutics, Inc., Managing Director-Healthcare Investment Ban at TAG Healthcare Advisors LLC, Research Associate at ImmuLogic Pharmaceutical Corp., Associate-Healthcare Investment Banking at JPMorgan H&Q Principals LP, Managing Director-Healthcare Investment Banking at GCA Savvian Advisors LLC, Managing Director-Healthcare Investment Banking at Montgomery & Co. and Managing Director at Sagent Advisors LLC. He received an MBA from The University of Chicago, a doctorate from the University of California and an undergraduate degree from the University of Washington.
Michael M. Mueller Michael M. Mueller occupies the position of Secretary, Vice President & General Counsel for Conatus Pharmaceuticals, Inc.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐